Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

13 results
Display

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study

Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, Lindner D, Adsul S

Background/Aims: The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment

Akiyama S, Rai V, Rubin DT

Patients with inflammatory bowel disease (IBD) occasionally need a restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) because of medically refractory colitis or dysplasia/cancer. However, pouchitis may develop in up to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study

Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S

Background/Aims: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T

Background/Aims: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Whipple disease mimicking inflammatory bowel disease

Tatsuki M, Ishige T, Igarashi Y, Hatori R, Hokama A, Hirato J, Muise A, Takizawa T, Arakawa H

Whipple disease is a systemic chronic infection caused by Tropheryma whipplei. Although chronic diarrhea is a common gastrointestinal symptom, diagnosis is often difficult because there are no specific endoscopic findings,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis

Shimizu H, Fujii T, Hibiya S, Motobayashi M, Suzuki K, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis

Jeong Y, Jeon SR, Kim HG, Moon JR, Lee TH, Jang JY, Cho JH, Park JS, Park H, Lee Kh, Kim JO, Lee JS, Ko BM, Park S

Background/Aims: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) can serve as biomarkers for diagnosing and assessing disease activity in ulcerative colitis (UC). We investigated their clinical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver

Agarwal A, Singh A, Mehtab W, Gupta V, Chauhan A, Rajput MS, Singh N, Ahuja V, Makharia GK

Background/Aims: Gluten-free diet has an excess of fats and simple sugars and puts patients with celiac disease at risk of metabolic complications including metabolic syndrome and fatty liver. We assessed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis

Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H

Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases

Limsrivilai J, Pausawasdi N

Differentiating Crohn’s disease (CD) from intestinal tuberculosis (ITB) is a diagnostic dilemma, particularly in regions where ITB is prevalent and CD incidence is increasing, because both diseases can present quite...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Endoscopic molecular imaging in inflammatory bowel disease

Ham NS, Myung SJ

Molecular imaging is a technique for imaging the processes occurring in a living body at a molecular level in real-time, combining molecular cell biology with advanced imaging technologies using molecular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Quality of life in inflammatory bowel diseases: it is not all about the bowel

Keller R, Mazurak N, Fantasia L, Fusco S, Malek NP, Wehkamp J, Enck P, Klag T

Background/Aims: The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two intertwined compartments coexisting in sporadic conventional colon adenomas

Rubio CA

Sporadic conventional colon adenomas are microscopically built of 2 intertwined compartments: one on top, harboring the dysplastic tissue that defines their histo-biomolecular attributes, and the other below, composed of non-dysplastic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr